Investigational therapies for celiac disease

Bibliography

• Mäki M, Mustalahti K, Kokkonen J, Prevalence of celiac disease among children in Finland. N Engl J Med 2003;348:2517-24
   PubMed Web of Science ®Google Scholar
• Vilppula A, Collin P, Mäki M, Undetected celiac disease in the elderly. A biopsy-proven population-based study. Dig Liver Dis 2008;40:809-13
   PubMedGoogle Scholar
• Green PH, Jabri B. Coeliac disease. Lancet 2003;362:383-91
   PubMed Web of Science ®Google Scholar
• Rodrigo L. Celiac disease. World J Gastroenterol 2006;12:6585-93
   PubMed Web of Science ®Google Scholar
• Kagnoff MF. Celiac disease: pathogenesis of a model immunogenetic disease. J Clin Invest 2007;117:41-9
   PubMed Web of Science ®Google Scholar
• Molberg O, Solheim Flaete N, Jensen T, Intestinal T-cell responses to high-molecular-weight glutenins in celiac disease. Gastroenterology 2003;125:337-44
   PubMed Web of Science ®Google Scholar
• Maiuri L, Ciacci C, Ricciardelli I, Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease. Lancet 2003;362:30-7
   PubMed Web of Science ®Google Scholar
• Dewar DH, Amato M, Ellis HJ, The toxicity of high molecular weight glutenin subunits of wheat to patients with coeliac disease. Eur J Gastroenterol Hepatol 2006;18:483-91
   PubMed Web of Science ®Google Scholar
• Rashtak S, Murray JA. Tailoring testing for celiac disease. Ann Intern Med 2007;147:339-41
   PubMed Web of Science ®Google Scholar
• Van Heel DA, Franke L, Hunt KA, A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat Genet 2007;39:827-9
   PubMed Web of Science ®Google Scholar
• Hunt KA, Zhernakova A, Turner G, Newly identified genetic risk variants for celiac disease related to the immune response. Nat Genet 2008;40:395-402
   PubMed Web of Science ®Google Scholar
• Dieterich W, Ehnis T, Bauer M, Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 1997;3:797-801
   PubMed Web of Science ®Google Scholar
• Koo, van Veelen P, Peña S, Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity. J Immunol 1998;161:1585-8
   PubMed Web of Science ®Google Scholar
• Molberg O, McAdam SN, Körner R, Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat Med 1998;4:713-7
   PubMed Web of Science ®Google Scholar
• Esposito C, Paparo F, Caputo I, Expression and enzymatic activity of small intestinal tissue transglutaminase in celiac disease. Am J Gastroenterol 2003;98:1813-20
   PubMed Web of Science ®Google Scholar
• Kim C, Quarsten H, Bergseng E, Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease. Proc Natl Acad Sci USA 2004;101:4175-9
   PubMed Web of Science ®Google Scholar
• Dieterich W, Esslinger B, Trapp D, Cross-linking to tissue transglutaminase and collagen favours gliadin toxicity in coeliac disease. Gut 2006;55:478-84
   PubMed Web of Science ®Google Scholar
• Mention JJ, Ben Ahmed M, Bègue B, Interleukin 15: a key to disrupted intraepithelial lymphoctye homeostasis and lymphomagenesis in celiac disease. Gastroenterology 2003;125:730-45
   PubMed Web of Science ®Google Scholar
• Di Sabatino A, Ciccocioppo R, Cupelli F, Epithelium derived interleukin 15 regulates intraepithelial lymphocyte Th1 cytokine production, cytotoxicity and survival in coeliac disease.Gut 2006;55:469-77
   Google Scholar
• Jabri B, de Serre NP, Cellier C, Selective expansion of intraepithelial lymphocytes expressing the HLA-E-specific natural killer receptor CD94 in celiac disease. Gastroenterology 2000;118:867-79
   PubMed Web of Science ®Google Scholar
• Martín-Pagola A, Pérez-Nanclares G, Ortiz L, response to gliadin in intestinal mucosa from celiac patients. Immunogenetics 2004;56:549-54
   PubMed Web of Science ®Google Scholar
• Benahmed M, Meresse B, Arnulf B, Inhibition of TGF-beta signaling by IL-15: a new role for IL-15 in the loss of immune homeostasis in celiac disease. Gastroenterology 2007;132:994-1008
   PubMed Web of Science ®Google Scholar
• Vahedi K, Mascart F, Mar J, Reliability of anti-transglutaminase antibodies as predictors of gluten-free diet compliance in adult celiac disease. Am J Gastroenterol 2003;98:1079-87
   PubMed Web of Science ®Google Scholar
• Catassi C, Fabiani E, Iacono G, A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. Am J Clin Nutr 2007;85:160-6
   PubMed Web of Science ®Google Scholar
• Wagner G, Berger G, Sinnreich U, Quality of life in adolescents with treated coeliac disease: influence of compliance and age at diagnosis. J Pediatr Gastroenterol Nutr 2008;47:555-61
   PubMed Web of Science ®Google Scholar
• O'Leary C, Wieneke P, Healy M, Celiac disease and the transition from childhood to adulthood: a 28-year follow-up. Am J Gastroenterol 2004;99:2437-41
   PubMed Web of Science ®Google Scholar
• Olsson C, Lyon P, Hörnell A, Food that makes you different: the stigma experienced by adolescents with celiac disease. Qual Health Res 2009;19:976-84
   PubMed Web of Science ®Google Scholar
• Casellas F, Rodrigo L, Vivancos JL, Factors that impact health-related quality of life in adults with celiac disease: a multicenter study. World J Gastroenterol 2008;14:46-52
   PubMed Web of Science ®Google Scholar
• Shan L, Marti T, Sollid LM, Comparative biochemical analysis of three bacterial prolyl endopeptidases: implications for coeliac sprue. Biochem J 2004;383:311-8
   PubMed Web of Science ®Google Scholar
• Pyle GG, Paaso B, Anderson BE, Effect of pretreatment of food gluten with prolyl endopeptidase on gluten-induced malabsorption in celiac sprue. Clin Gastroenterol Hepatol 2005;3:687-94
   PubMed Web of Science ®Google Scholar
• Marti T, Molberg O, Li Q, Prolyl endopeptidase-mediated destruction of T cell epitopes in whole gluten: chemical and immunological characterization. J Pharmacol Exp Ther 2005;312:19-26
   PubMed Web of Science ®Google Scholar
• Chen YS, Christensen JE, Broadbent JR, Steele JL Identification and characterization of lactobacillus helveticus PepO2, an endopeptidase with post-proline specificity. Appl Environ Microbiol 2003;69:1276-82
   PubMed Web of Science ®Google Scholar
• Mitea C, Havenaar R, Drijfhout JW, Efficient degradation of gluten by a prolyl endoprotease in a gastrointestinal model: implications for coeliac disease. Gut 2008;57:25-32
   PubMed Web of Science ®Google Scholar
• Gass J, Bethune MT, Siegel M, Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue. Gastroenterology 2007;133:472-80
   PubMed Web of Science ®Google Scholar
• Di Cagno R, Rizzello CG, De Angelis M, Use of selected sourdough strains of lactobacillus for removing gluten and enhancing the nutritional properties of gluten-free bread. J Food Prot 2008;71:1491-5
   PubMed Web of Science ®Google Scholar
• Matysiak-Budnik T, Candalh C, Cellier C, Limited efficiency of prolyl-endopeptidase in the detoxification of gliadin peptides in celiac disease. Gastroenterology 2005;129:786-96
   PubMed Web of Science ®Google Scholar
• Fasano A, Not T, Wang W, Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease. Lancet 2000;355:1518-9
   PubMed Web of Science ®Google Scholar
• Lammers KM, Lu R, Brownley J, Gliadin induces an increase in intestinal permeability and zonulin release binding to the chemokine receptor CXCR3. Gastroenterology 2008;135:194-204
   PubMed Web of Science ®Google Scholar
• Drago S, El Asmar R, Di Pierro M, Gliadin, zonulin and gut permeability: effects on celiac and non-celiac intestinal mucosa and intestinal cell lines. Scand J Gastroenterol 2006;41:408-19
   PubMed Web of Science ®Google Scholar
• Paterson BM, Lammers KM, Arrieta MC, The safet, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther 2007;26:757-66
   PubMed Web of Science ®Google Scholar
• Baldassarre M, Laneve AM, Grosso R, Celiac disease: pathogenesis and novel therapeutic strategies. Endocr Metab Immune Disord Drug Targets 2008;8:152-8
   PubMedGoogle Scholar
• Szond Z, Sarang Z, Molnar P, Transglutaminase 2-/- mice reveal a phagocytosis-associated crosstalk between macrophages and apoptotic cells. Proc Natl Acad Sci USA 2003;100:7812-7
   PubMed Web of Science ®Google Scholar
• Freund KF, Doshi KP, Gaul SL, Transglutaminase inhibition by 2-[(2-oxopropyl)thio] imidazolium derivatives: mechanism of factor XIIIa inactivation. Biochemistry 1994;33:10.109-19
   Google Scholar
• Choi K, Siegel M, Piper JL, Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2. Chem Biol 2005;12:469-75
   PubMed Web of Science ®Google Scholar
• Telci D, Griffin M. Tissue transglutaminase (TG2)–a wound response enzyme. Front Biosci 2006;11:867-82
   PubMed Web of Science ®Google Scholar
• Silano M, Di Benedetto R, Trecca A, A decapeptide from durum wheat prevents celiac peripheral blood lymphocytes from activation by gliadin peptides. Pediatr Res 2007;61:67-71
   PubMed Web of Science ®Google Scholar
• Siegel M, Xia J, Khosla C. Structure-based design of alpha-amido aldehyde containing gluten peptide analogues as modulators of HLA-DQ2 and transglutaminase 2. Bioorg Med Chem 2007;15:6253-61
   PubMed Web of Science ®Google Scholar
• Xia J, Bergseng E, Fleckenstein B, Cyclic and dimeric gluten peptide analogues inhibiting DQ2-mediated antigen presentation in celiac disease. Bioorg Med Chem 2007;15:6565-73
   PubMed Web of Science ®Google Scholar
• Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol 2003;3:123-32
   PubMed Web of Science ®Google Scholar
• Burkly LC. CD40 pathway blockade as an approach to immunotherapy. Adv Exp Med Biol 2001;489:135-52
   PubMed Web of Science ®Google Scholar
• Appel H, Seth NP, Gauthier L, Anergy induction by dimeric TCR ligands. J Immunol 2001;166:5279-85
   PubMed Web of Science ®Google Scholar
• Maurano F, Siciliano RA, De Giulio B, Intranasal administration of one alpha gliadin can down-regulate the immune response to whole gliadin in mice. Scand J Immunol 2001;53:290-5
   PubMed Web of Science ®Google Scholar
• Camarca A, Anderson RP, Mamone G, Intestinal T cell responses to gluten peptides are largely heterogeneous: implications for a peptide-based therapy in celiac disease. J Immunol 2009;182:4158-66
   PubMed Web of Science ®Google Scholar
• Monteleone I, Monteleone G, Del Vecchio Blanco G, Regulation of the T helper cell type 1 transcription factor T-bet in coeliac disease mucosa. Gut 2004;53:1090-5
   PubMed Web of Science ®Google Scholar
• Ciccocioppo R, Di Sabatino A, Bauer M, Matrix metalloproteinase pattern in celiac duodenal mucosa. Lab Invest 2005;85:397-407
   PubMed Web of Science ®Google Scholar
• Di Sabatino A, Ciccocioppo R, D'Alò S, Intraepithelial and lamina propria lymphocytes show distinct patterns of apoptosis whereas both populations are active in Fas based cytotoxicity in coeliac disease. Gut 2001;49:380-6
   PubMed Web of Science ®Google Scholar
• Monteleone G, Pender SL, Wathen NC, Interferon-alpha drives T cell-mediated immunopathology in the intestine. Eur J Immunol 2001;31:2247-55
   PubMed Web of Science ®Google Scholar
• Dema B, Martínez A, Fernández-Arquero M, The IL6-174G/C polymorphism is associated with celiac disease susceptibility in girls. Hum Immunol 2009;70:191-4
   PubMed Web of Science ®Google Scholar
• Salvati VM, MacDonald TT, Bajaj-Elliott M, Interleukin 18 and associated markers of T helper cell type 1 activity in coeliac disease. Gut 2002;50:186-90
   PubMed Web of Science ®Google Scholar
• Fina D, Sarra M, Caruso R, Interleukin 21 contributes to the mucosal T helper cell type 1 response in coeliac disease. Gut 2008;57:887-92
   PubMed Web of Science ®Google Scholar
• Forsberg G, Hernell O, Melgar S, Paradoxical coexpression of proinflammatory and down-regulatory cytokines in intestinal T cells in childhood celiac disease. Gastroenterology 2002;123:667-78
   PubMed Web of Science ®Google Scholar
• Di Sabatino A, Pickard KM, Gordon JN, Evidence for the role of interferon-alfa production by dendritic cells in the Th1 response in celiac disease. Gastroenterology 2007;133:1175-87
   PubMed Web of Science ®Google Scholar
• Salvati VM, Mazzarella G, Gianfrani C, Recombinant human interleukin 10 suppresses gliadin dependent T cell activation in ex vivo cultured coeliac intestinal mucosa. Gut 2005;54:46-53
   PubMed Web of Science ®Google Scholar
• Mulder CJ, Wahab PJ, Meijer JW, A pilot study of recombinant human interleukin-10 in adults with refractory coeliac disease. Eur J Gastroenterol Hepatol 2001;13:1183-8
   PubMed Web of Science ®Google Scholar
• Herfarth H, Schölmerich J. IL-10 therapy in Crohn's disease: at the crossroads. Treatment of Crohn's disease with the anti-inflammatory cytokine interleukin 10. Gut. 2002;50:146-7
   PubMed Web of Science ®Google Scholar
• Korzenik JR, Podolsky DK. Evolving knowledge and therapy of inflammatory bowel disease. Nat Rev Drug Discov 2006;5:197-209
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, Crohn's disease: beyond antagonists of tumour necrosis factor. Lancet 2008;372:67-81
   PubMed Web of Science ®Google Scholar
• Meresse B, Chen Z, Ciszewski C, Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 2004;21:357-66
   PubMed Web of Science ®Google Scholar
• Bernardo D, Garrote JA, Allegretti, Higher constitutive IL15R alpha expression and lower IL-15 response threshold in coeliac disease patients. Clin Exp Immunol 2008;154:64-73
   PubMed Web of Science ®Google Scholar
• Baslund B, Tvede N, Danneskiold-Samsoe B, Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum 2005;52:2686-92
   PubMed Web of Science ®Google Scholar
• Ferrari-Lacraz S, Zanelli E, Neuberg M, Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis. J Immunol 2004;173:5818-26
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan BG, Fedorak RN, Natalizumab for the treatment of active crohn's disease: results of the ENCORE Trial. Gastroenterology 2007;132:1672-83
   PubMed Web of Science ®Google Scholar
• Rose JW, Fole J, Carlson N. Monoclonal antibody treatments for multiple sclerosis. Curr Neurol Neurosci Rep 2008;8:419-26
   PubMed Web of Science ®Google Scholar
• Feagan BG, Greenberg GR, Wild G, Treatment of ulcerative colitis with a humanized antibody to the alpha-4, beta-7 integrin. N Engl J Med 2005;352:2499-507
   PubMed Web of Science ®Google Scholar
• Hüe S, Mention JJ, Monteiro RC, A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 2004;21:367-77
   PubMed Web of Science ®Google Scholar
• Caillat-Zucman S. How NKG2D ligands trigger autoimmunity. Hum Immunol 2006;67:204-7
   PubMed Web of Science ®Google Scholar
• Ogasawara K, Hamerman JA, Ehrlich LR, NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity 2004;20:757-67
   PubMedGoogle Scholar
• Nadal I, Donat E, Ribes-Koninckx C, Imbalance in the composition of the duodenal microbiota of children with coeliac disease. J Med Microbiol 2007;56:1669-74
   PubMed Web of Science ®Google Scholar
• Collado MC, Calabuig M, Sanz. Differences between the fecal microbiota of coeliac infants and healthy controls. Curr Issues Intest Microbiol 2007;8:9-14
   PubMedGoogle Scholar
• Li Q, Zhang Q, Wang M, Interferon-gamma and tumor necrosis factor-alpha disrupt epithelial barrier function by altering lipid composition in membrane microdomains of tight junction. Clin Immunol 2008;126:67-80
   PubMed Web of Science ®Google Scholar
• Zeng J, Li Q, Zuo XL, Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2008;28:994-1002
   PubMed Web of Science ®Google Scholar
• Seth A, an F, Polk DB, Rao RK. Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PKC- and MAP kinase-dependent mechanism. Am J Physiol Gastrointest Liver Physiol 2008;294:G1060-9
   PubMed Web of Science ®Google Scholar
• Lindfors K, Blomqvist T, Juuti-Uusitalo K, Live probiotic bifidobacterium lactis bacteria inhibit the toxic effects induced by wheat gliadin in epithelial cell culture. Clin Exp Immunol 2008;152:552-8
   PubMed Web of Science ®Google Scholar
• Medina M, Izquierdo E, Ennahar S, Sanz. Differential immunomodulatory properties of bifidobacterium logum strains: relevance to probiotic selection and clinical applications. Clin Exp Immunol 2007;150:531-8
   PubMed Web of Science ®Google Scholar
• Baba N, Samson S, Bourdet-Sicard R, Commensal bacteria trigger a full dendritic cell maturation program that promotes the expansion of non-Tr1 suppressor T cells. J Leukoc Biol 2008;84:468-76
   PubMed Web of Science ®Google Scholar
• Schuppan D, Junker. Turning swords into plowshares: transglutaminase to detoxify gluten. Gastroenterology 2007;133:1025-8
   PubMed Web of Science ®Google Scholar
• Londei M, Maiuri L, Quaratino S. A search for the hol grail: non-toxic gluten for celiac patients. Gastroenterology 2005;129:1111-3
   PubMed Web of Science ®Google Scholar
• Molberg O, Uhlen AK, Jensen T, Mapping of gluten T-cell epitopes in the bread wheat ancestors: implications for celiac disease. Gastroenterology 2005;128:393-401
   PubMed Web of Science ®Google Scholar
• Vader LW, Stepniak DT, Bunnik EM, Characterization of cereal toxicity for celiac disease patients based on protein homology in grains. Gastroenterology 2003;125:1105-13
   PubMed Web of Science ®Google Scholar
• Ciacci C, Maiuri L, Caporaso N, Celiac disease: in vitro and in vivo safety and palatability of wheat-free sorghum food products. Clin Nutr 2007;26:799-805
   PubMed Web of Science ®Google Scholar
• Spaenij-Dekking L, Koo-Winkelaar, van Veelen P, Natural variation in toxicity of wheat: potential for selection of nontoxic varieties for celiac disease patients. Gastroenterology 2005;129:797-806
   PubMed Web of Science ®Google Scholar
• Pinier M, Verdu EF, Nasser-Eddine M, Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium. Gastroenterology 2009;136:288-98
   PubMed Web of Science ®Google Scholar
• Silano M, Leonardi F, Trecca A, Prevention by a decapeptide from durum wheat of in vitro gliadin peptide-induced apoptosis in small-bowel mucosa from coeliac patients. Scand J Gastroenterol 2007;42:786-7
   PubMed Web of Science ®Google Scholar
• Silano M, Di Benedetto R, Maialetti F, A 10-residue peptide from durum wheat promotes a shift from a Th1-type response toward a Th2-type response in celiac disease. Am J Clin Nutr 2008;87:415-23
   PubMed Web of Science ®Google Scholar
• Maiden L, Elliott T, McLaughlin SD, Ciclitira P. A blinded pilot comparison of capsule endoscopy and small bowel histology in unresponsive celiac disease. Dig Dis Sci 2009;54:1280-3
   PubMed Web of Science ®Google Scholar
• Murray JA, Rubio-Tapia A, Van Dke CT, Mucosal atrophy in celiac disease: extent of. Clin Gastroenterol Hepatol 2008;6:186-93
   PubMed Web of Science ®Google Scholar
• Sollid LM, Khosla. Future therapeutic options for celiac disease. Nat Clin Pract Gastroenterol Hepatol 2005;2:140-7
   PubMedGoogle Scholar
• Briani C, Samaroo D, Alaedini A. Celiac disease: from gluten to autoimmunity. Autoimmun Rev 2008;7:644-50
   PubMed Web of Science ®Google Scholar
• Bethune MT, Borda JT, Ribka E, A non-human primate model for gluten sensitivity. PLoS One 2008;3:e1614
   PubMed Web of Science ®Google Scholar
• Gianfrani C, Levings MK, Sartivana C, Gliadin-specific type 1 regulatory T cells from the intestinal mucosa of treated celiac patients inhibits pathogenic T cells. J Immunol 2006;177:4178-86
   PubMed Web of Science ®Google Scholar
• Lerner A. New therapeutic strategies for celiac disease. Autoimmun Rev 2009 [E-pub ahead of print]; doi:10-1016/j.autrev.2009.05.002
   Google Scholar
• Sanz Y. Novel perspectives in celiac disease therapy. Mini Rev Med Chem 2009;9:359-67
   PubMed Web of Science ®Google Scholar